A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity and Safety of 9- Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine (V503) in Chinese Females 9 to 45 Years of Age
Latest Information Update: 26 Mar 2025
At a glance
- Drugs V 503 (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 24 Mar 2025 Status changed from active, no longer recruiting to completed.
- 27 Jan 2025 Planned End Date changed from 18 Jan 2025 to 28 Feb 2025.
- 27 Jan 2025 Planned primary completion date changed from 18 Jan 2025 to 28 Feb 2025.